Euroapi SAS banner
E

Euroapi SAS
PAR:EAPI

Watchlist Manager
Euroapi SAS
PAR:EAPI
Watchlist
Price: 2.184 EUR -2.5% Market Closed
Market Cap: €208.8m

P/OCF

3
Current
32%
Cheaper
vs 3-y median of 4.4

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
3
=
Market Cap
€202.6m
/
Operating Cash Flow
€69.9m

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
3
=
Market Cap
€202.6m
/
Operating Cash Flow
€69.9m

Valuation Scenarios

Euroapi SAS is trading below its 3-year average

If P/OCF returns to its 3-Year Average (4.4), the stock would be worth €3.21 (47% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+237%
Average Upside
114%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 3 €2.18
0%
3-Year Average 4.4 €3.21
+47%
5-Year Average 4.4 €3.21
+47%
Industry Average 10 €7.37
+237%
Country Average 6.7 €4.95
+127%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
FR
Euroapi SAS
PAR:EAPI
207.9m EUR 3 -1.7
US
Eli Lilly and Co
NYSE:LLY
965.7B USD 60.1 46.8
US
Johnson & Johnson
NYSE:JNJ
594B USD 24.2 22.2
CH
Roche Holding AG
SIX:ROG
291.5B CHF 15.2 31
UK
AstraZeneca PLC
LSE:AZN
236.4B GBP 22.1 31.6
CH
Novartis AG
SIX:NOVN
242.5B CHF 16.3 22.3
US
Merck & Co Inc
NYSE:MRK
303.7B USD 17.8 16.6
IE
Endo International PLC
LSE:0Y5F
218B USD 809.8 -74.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 11.5 13.3
US
Pfizer Inc
NYSE:PFE
152.2B USD 11.6 19.6
UK
GSK plc
XETRA:GS71
105.9B EUR 11.9 16.1
P/E Multiple
Earnings Growth PEG
FR
E
Euroapi SAS
PAR:EAPI
Average P/E: 24.4
Negative Multiple: -1.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.8
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22.2
7%
3.2
CH
Roche Holding AG
SIX:ROG
31
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
31.6
26%
1.2
CH
Novartis AG
SIX:NOVN
22.3
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.6
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
7%
1.9
US
Pfizer Inc
NYSE:PFE
19.6
26%
0.8
UK
GSK plc
XETRA:GS71
16.1
18%
0.9

Market Distribution

Lower than 81% of companies in France
Percentile
19th
Based on 1 511 companies
19th percentile
3
Low
0 — 4.4
Typical Range
4.4 — 12
High
12 —
Distribution Statistics
France
Min 0
30th Percentile 4.4
Median 6.7
70th Percentile 12
Max 2 287.4

Euroapi SAS
Glance View

Market Cap
208.8m EUR
Industry
Pharmaceuticals

EUROAPI SA operates as a manufacturer and supplier of active pharmaceutical ingredient solutions for healthcare companies. The company is headquartered in Paris, Ile-De-France and currently employs 3,342 full-time employees. The company went IPO on 2022-05-06. The firm is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc. ), analgesics, etc. The firm also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. The company has production sites located in France, the United Kingdom, Germany, Italy and Hungary.

EAPI Intrinsic Value
6.335 EUR
Undervaluation 66%
Intrinsic Value
Price
E